# Popular search #
# Popular search #
To disseminate and promote leading scientific advances and knowledge in diabetes research, treatment, education, and advocacy, the International Diabetes Federation (IDF) will host the IDF Virtual Congress 2023 from December 4 to 7, focusing on diabetes-related complications. During the conference, more than 130 international experts will discuss the latest research, treatments and tools to manage, treat and prevent diabetes complications1.
The IDF Virtual Congress 2023 will featurethree dedicated streams offering the latest scientific advances in the management and prevention of diabetes complications affecting the cardiovascular system, eyes, kidneys, feet and nerves. A fourth stream will focus on the impact of natural and man-made disasters on people living with diabetes and the long-term effects of Covid-19. All four streams will include the experiences of people living with diabetes, which play a key role in understanding, managing and preventing diabetes complications1. Additionally, the conference will introduce the latest epidemiological and impact data on diabetes complications fromthe IDF Diabetes Altason the opening day, the 4th of December.
During the four-day high-level conference, the results of Gan & Lee Pharmaceuticals' independently developed insulin aspart 70/30 (Rapilin®️30) Phase III clinical study in China will be presented in an e-Poster format in the virtual conference's e-Poster Gallery, giving attendees ample opportunity to learn about the clinical research achievements of Rapilin®️30 through IDF's virtual platform.
Gan & Lee Pharmaceuticals Insulin Aspart 30 (Rapilin®️ 30)
Efficacy and safety of GL insulin aspart 70/30 compared with reference insulin in Chinese patients with DM
Principal Investigator: Wenying Yang丨 China-Japan Friendship Hospital, China
Presenter: Xin Wang丨China-Japan Friendship Hospital, China
IDF Virtual Congress 2023 Venue2
Rapilin®️30 Phase III Clinical Study
The Phase III clinical study of Gan & Lee insulin aspart 70/30 (Rapilin®️30) in China aims to demonstrate the similar efficacy and safety of Gan & Lee Pharmaceuticals' Rapilin®️30 in patients with Type 1 and Type 2 diabetes compared to the reference product NovoRapid®️30. The study, using a randomized, open-label, parallel-controlled trial design, involved 569 patients with Type 1 and Type 2 diabetes, exploring the bioequivalence in efficacy and safety of Rapilin®️30 compared to NovoRapid®️30 after 24 weeks of continuous administration.
International Diabetes Federation (IDF)
The International Diabetes Federation (IDF) is an umbrella organization of over 230 national diabetes associations in 170 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950.
The IDF Congress is one of the largest health conferences globally, aimed at disseminating and promoting leading scientific advances and knowledge in diabetes research, treatment, education, and advocacy. The detailed schedule of IDF 2023 is now available on the official website. For more information, please visit IDF Virtual Congress 2023 official website: https://idf2023.org/
1. WELCOME MESSAGE FROM THE PROGRAMME CHAIR. IDF Virtual Congress 2023. https://idf2023.org/welcome/
2. 【IDF Virtual Congress 2023】Focusing on Diabetes Complications. IDF WeChat Platform. https://mp.weixin.qq.com/s/HK8L0IHL8M1_8OBsUZUh7Q
The site you are about to visit is maintained by a third party who is responsible for its content.